Analysts Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) PT at $9.60

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been assigned an average rating of “Hold” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $9.60.

A number of analysts have recently commented on VRCA shares. Royal Bank of Canada downgraded Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $11.00 to $2.00 in a report on Tuesday, November 5th. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, November 5th. HC Wainwright downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 6th. Finally, TD Cowen reduced their price target on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st.

Institutional Trading of Verrica Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of Verrica Pharmaceuticals during the second quarter worth $50,000. Key Financial Inc purchased a new position in Verrica Pharmaceuticals in the 2nd quarter valued at about $69,000. Rhumbline Advisers grew its stake in shares of Verrica Pharmaceuticals by 20.4% during the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after acquiring an additional 4,514 shares in the last quarter. Barclays PLC increased its position in shares of Verrica Pharmaceuticals by 404.6% during the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after acquiring an additional 25,130 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Verrica Pharmaceuticals in the second quarter worth about $332,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Price Performance

VRCA opened at $0.89 on Friday. Verrica Pharmaceuticals has a 12 month low of $0.70 and a 12 month high of $11.41. The business has a 50-day moving average of $1.41 and a two-hundred day moving average of $4.74. The company has a debt-to-equity ratio of 29.58, a current ratio of 1.34 and a quick ratio of 1.22. The stock has a market capitalization of $40.58 million, a price-to-earnings ratio of -0.49 and a beta of 1.45.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Monday, November 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The company had revenue of ($1.78) million during the quarter, compared to analysts’ expectations of $7.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. On average, research analysts expect that Verrica Pharmaceuticals will post -1.42 earnings per share for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.